3D InSight™ Short-term Hepatotoxicity Testing Service

Why choose short-term hepatotoxicity testing?

  • Offers rapid in vitro hepatotoxic characterization in organotypic 3D microtissue models
  • Multiple species available allowing translational comparison to existing in vivo data
  • Enables compound prioritization before entering cost-intensive animal studies

 

3D Model Systems:

STT

learn more about Human Islet Microtissues    quote

  • For pricing information and shipping costs, please indicate the quantity of compounds you'd like to test and desired service completion date in the quote request form.

    Catalog # Description
    SP-02-010-01 3D InSight™Short-term Hepatotoxicity Testing – 5 compounds
    SP-02-010-02 3D InSight™Short-term Hepatotoxicity Testing - 10 compounds
    SP-02-010-03 3D InSight™Short-term Hepatotoxicity Testing - 20 compounds

     

    Related Services

    DILI Evaluation Service

    Cross-species hepatotoxicity testing

     

  • Model systems

    3D InSight™ Human, Rat or Dog Liver Microtissues (Minipig, Cynomolgus beta test species also available)

    Exposure time

    7 days. Initial dosing at day 0, repeat dosing at day 3.

    xspecies dosing

    Figure 1. Schematic outline of short-term hepatotoxicity testing. Liver microtissues are initially treated with compound (Day 0) and re-dosed at Day 3. On Day 7, the microtissues are subjected to ATP measurement using CellTiter-Glo® assay.

    Endpoints

    ATP (intracellular - Promega CellTiter-Glo®), other endpoints upon request
    Promega mini

    Test compound concentration

    7 point dose-response curve, each data point in triplicate.

    Compound requirements

    50 μl from a 200X stock (in DMSO), or powder equivalent

    Quality control

    0.5% DMSO, Chlorpromazine (positive control)

    Data delivery

    Dose response curve, IC50 +/- confidence intervals, written report

    xspecies charts

    Figure 2. Dose-response curves for human, dog and rat liver microtissues for 7 days exposure to increasing concentrations of Diclofenac. Curves demonstrate cell viability as determined by Promega CellTiter-Glo® at day 7 of exposure.

    References

    Foster, A., Summers, C., Sidaway, J., Messner, S., Haugstetter, J., Rutt, T., Hockings, P., Oldman, K. and Williams, D. "Evaluation of 3D InSightTM human liver microtissues for the detection of compounds that cause drug-induced liver injury in humans". Astra Zeneca IVTS 2014 Poster Presentation. Reprint upon request

    Messner, S., Agarkova, I., Moritz, W., & Kelm, J.M. (2012). Multi-cell type human liver microtissues for hepatotoxicity testing. Archives of toxicology, 87(1),209-13.

    Kratschmar, D.V., Messner, S., Moritz, W., & Odermatt, A. Characterization of a Rat Multi-Cell Type 3D-Liver Microtissue Sstem. Tissue Science & Energeering, 4(2), 130.

     

    • Organotypic primary hepatocyte model with high functionality over 4 weeks
    • Enables repeat dosing experiments
    • Co-culture with non-parenchymal cells, including Kupffer cells
    • Optimized Promega CellTiter-Glo® assay
    • No bioartificial matrices
  • Support

    Please send your inquiry to This email address is being protected from spambots. You need JavaScript enabled to view it. or contact This email address is being protected from spambots. You need JavaScript enabled to view it. for pricing/ quotation matters.

    Documents and downloads

    Product brochure

    Webinar: 3D liver models for more predictive toxicology and drug efficacy testing

Company video

company-video-inspheor